D
Daniel A. Filippa
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 116
Citations - 8121
Daniel A. Filippa is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Lymphoma & Non-Hodgkin's lymphoma. The author has an hindex of 49, co-authored 116 publications receiving 7924 citations. Previous affiliations of Daniel A. Filippa include Memorial Hospital of South Bend & Kettering University.
Papers
More filters
Journal ArticleDOI
A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model
Craig H. Moskowitz,Stephen D. Nimer,Andrew D. Zelenetz,Tania Trippett,Eric Hedrick,Daniel A. Filippa,Diane C. Louie,Maria Gonzales,Janine Walits,Nancy Coady-Lyons,Jing Qin,Richard C. Frank,Joseph R. Bertino,Andre Goy,Ariela Noy,James P. O'Brien,David J. Straus,Carol S. Portlock,Joachim Yahalom +18 more
TL;DR: These results compare favorably with other series and document the feasibility and efficacy of giving uniform dose-dense and dose-intense cytoreductive chemotherapy and integrating accelerated fractionation radiotherapy into an ASCT treatment program.
Journal ArticleDOI
Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma
Kenneth Offit,Francesco Lo Coco,Francesco Lo Coco,Diane C. Louie,Nasser Z. Parsa,Denis H. Y. Leung,Carol S. Portlock,Bihui H. Ye,Florigio Lista,Daniel A. Filippa,Ayala Rosenbaum,Marc Ladanyi,Suresh C. Jhanwar,Riccardo Dalla-Favera,R.S.K. Chaganti +14 more
TL;DR: Rearrangement of the bcl-6 gene correlated with a favorable clinical outcome in DLLC and may thus serve as a prognostic marker in patients with this form of malignant lymphoma.
Journal ArticleDOI
Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma
Tarun Kewalramani,Andrew D. Zelenetz,Stephen D. Nimer,Carol S. Portlock,David J. Straus,Ariela Noy,Owen A. O'Connor,Daniel A. Filippa,Julie Teruya-Feldstein,Alison Gencarelli,Jing Qin,Alyson Waxman,Joachim Yahalom,Craig H. Moskowitz +13 more
TL;DR: RICE appears to induce very high CR rates in patients with relapsed and refractory DLBCL; however, further studies are necessary to determine whether this treatment regimen will improve outcomes after ASCT.
Journal ArticleDOI
Risk-Adapted Dose-Dense Immunochemotherapy Determined by Interim FDG-PET in Advanced-Stage Diffuse Large B-Cell Lymphoma
Craig H. Moskowitz,Heiko Schöder,Julie Teruya-Feldstein,Camelia Sima,Alexia Iasonos,Carol S. Portlock,David J. Straus,Ariela Noy,Maria Lia Palomba,Owen A. O'Connor,Steven M. Horwitz,Sarah A. Weaver,Jessica Meikle,Daniel A. Filippa,James F. Caravelli,Paul A. Hamlin,Andrew D. Zelenetz +16 more
TL;DR: Interim or post-treatment FDG-PET evaluation did not predict outcome with this dose-dense, sequential immunochemotherapy program, and outside of a clinical trial, it is recommended to recommend biopsy confirmation of an abnormal interim FDg-PET scan before changing therapy.
Journal ArticleDOI
Ifosfamide, Carboplatin, and Etoposide: A Highly Effective Cytoreduction and Peripheral-Blood Progenitor-Cell Mobilization Regimen for Transplant-Eligible Patients With Non-Hodgkin's Lymphoma
Craig H. Moskowitz,Joseph R. Bertino,Jill R. Glassman,Eric Hedrick,Sonia Hunte,Nancy Coady-Lyons,David B. Agus,Andre Goy,Joseph G. Jurcic,Ariela Noy,James P. O'Brien,Carol S. Portlock,David Straus,Barrett H. Childs,Richard C. Frank,Joachim Yahalom,Daniel A. Filippa,Diane C. Louie,Stephen D. Nimer,Andrew D. Zelenetz +19 more
TL;DR: ICE chemotherapy, with ifosfamide administered as a 24-hour infusion to decrease CNS side effects, and the substitution of carboplatin for cisplatin to minimize nephrotoxicity, is a very effective cytoreduction and mobilization regimen in patients with NHL.